Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris
Completed · Phase 2
Conditions studied: Pemphigus Vulgaris
In brief
The purpose of the study is to find out about the effectiveness and the safety of an investigational drug called etanercept (Enbrel) to treat pemphigus vulgaris. Pemphigus vulgaris is a potentially life threatening blistering condition that currently has no cure. An investigational drug is one that has not been approved by the United States (US) Food and Drug Administration (FDA) to treat a particular condition or disease. Etanercept has been approved by the FDA to treat rheumatoid arthritis, juvenile rheumatoid arthritis, and psoriasis, but not pemphigus vulgaris.
Key facts
- Study ID
- NCT00135720
- Run by
- Massachusetts General Hospital
- People needed
- 12
- Starts
- 2004-06-01
- Expected to finish
- 2007-11-01
- Last updated by the study team
- 2015-06-03
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Clinical Unit for Research Trials in Skin — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.